Both in Pharmaceuticals
SELLAS Life Sciences Group vs Generate Biomedicines
Over the past year SLS returned −20.8% and GENB returned −9.9%; their daily moves had a correlation of 0.10.
SLS −20.8% GENB −9.9%Growth of $1, one year, split-adjusted
| Metric | SLS | GENB |
|---|---|---|
| Price | $9.14 | $14.16 |
| Market cap | $1.85B | $1.82B |
| Today | +3.04% | +2.24% |
| 1 month | −19.4% | +2.6% |
| 6 months | +77.5% | — |
| Year to date | +142.4% | — |
| 1 year | +410.6% | — |
| Revenue growth (YoY) | — | — |
| Gross margin | — | 100.0% |
| Net margin | — | −1065.2% |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $138.3M | $452.3M |
| Dividend yield | — | — |
| Volatility (60d) | 97.0% | — |
| Short % of float | 27.0% | 15.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).